Our study evaluated the clinical effectiveness, safety and tolerability of third-generation COMT inhibitor opicapone in patients with PD on levodopa treatment at the 6 months and 12 months follow-up period in a non-White and Emirati community in UAE. The gene discussed is COMT; the disease is Parkinson disease.